Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate

被引：0

作者：

Espinet, Blanca ^{[1
,3
]}

Carla Oliveira, Ana ^{[2
]}

Boque, Concepcion ^{[2
]}

Domingo, Alicia ^{[2
]}

Alonso, Esther ^{[2
]}

Sole, Francesc ^{[1
,3
]}

机构：

[1] Hosp del Mar, Lab Citogenet & Biol Mol, Serv Patol, IMAS,URNHE PRBB, Barcelona, Spain

[2] Hosp Univ Bellvitge, Serv Hematol, ICO, Barcelona, Spain

[3] Escola Citol Hematol Soledad Woessner IMAS, Barcelona, Spain

来源：

HAEMATOLOGICA | 2005年 / 90卷 / 04期

关键词：

chronic myeloid leukemia; clonal cytogenetic abnormalities; imatinib;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The emergence of clonal chromosomal abnormalities in Philadelphia-negative cells during treatment with imatinib in patients with Philadelphia-positive chronic myeloid leukemia has been reported. We add information to this issue presenting a series of 29 patients in complete cytogenetic response after imatinib treatment, three of whom developed clonal aberrations.

引用

页码：556 / 558

页数：4

共 50 条

[31] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
Sandip Ganguly
K. C. Lakshmaiah
Linu Abraham Jacob
Suresh Babu
Lokanatha Dasappa
K. S. Govind Babu
Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 82 - 86
[32] Immunological status of chronic myelogenous leukemia patients with complete cytogenetic response after treatment
Deng, Zhikui
Li, Yuanyuan
Li, Yu-feng
TUMORI, 2015, 101 (03) : 323 - 327
[33] Complex cytogenetic abnormalities in a patient with chronic myeloid leukemia: a case report
A. S. Lukyanova
B. Pienkowska-Grela
Z. V. Maslyak
Cytology and Genetics, 2009, 43 : 188 - 193
[34] Complex cytogenetic abnormalities in a patient with chronic myeloid leukemia: a case report
Lukyanova, A. S.
Pienkowska-Grela, B.
Maslyak, Z. V.
CYTOLOGY AND GENETICS, 2009, 43 (03) : 188 - 193
[35] The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years
Piazza, Rocco G.
Magistroni, Vera
Franceschino, Anna
Andreoni, Federica
Tornaghi, Lucia
Colnaghi, Federica
Corneo, Gianmarco
Pogliani, Enrico M.
Gambacorti-Passerini, Carlo
BLOOD CELLS MOLECULES AND DISEASES, 2006, 37 (02) : 111 - 115
[36] Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia
Natarajan, Harivenkatesh
Kumar, Lalit
Bakhshi, Sameer
Sharma, Atul
Velpandian, Thirumurthy
Kabra, Madhulika
Gogia, Ajay
Biswas, Nihar Ranjan
Gupta, Yogendra Kumar
LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 418 - 425
[37] Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response
Osorio, S.
Noblejas, A. Garcia
Duran, A.
Steegmann, J. L.
AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) : 394 - 395
[38] Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Yhim, Ho-Young
Lee, Na-Ri
Song, Eun-Kee
Yim, Chang-Yeol
Jeon, So Yeon
Shin, Seunghwan
Kim, Jeong-A
Kim, Hee Sun
Cho, Eun Hae
Kwak, Jae-Yong
LEUKEMIA RESEARCH, 2012, 36 (06) : 689 - 693
[39] Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate
Marin, D
Marktel, S
Foot, N
Bua, M
Olavarria, E
Goldman, JM
Apperley, JF
HAEMATOLOGICA, 2003, 88 (02) : 227 - 229
[40] Spotlight on Imatinib Mesylate in Chronic Myeloid Leukemia
Monique P. Curran
Katherine F. Croom
Karen L. Goa
BioDrugs, 2004, 18 : 207 - 210

← 1 2 3 4 5 →